Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...149150151152153154155156157158159...859860»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal, IO biomarker:  Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. (Pubmed Central) -  Jul 11, 2023   
    Blinatumomab could be an effective and safe salvage therapy in patients with R/R B-ALL who failed/progressed after anti-CD19-CAR T therapy, even in R/R B-ALL patients without high expression of CD19 in B-ALL cells, patients with CNS leukemia or co-infection.Key messagesSome R/R B-ALL patients did not respond to anti-CD19 CAR T-cell therapy or had a disease progression again. Effective and safe salvage therapy for such patients remains to be explored.Blinatumomab could be an effective and safe salvage therapy in patients with R/R B-ALL who failed/progressed after anti-CD19-CAR T therapy, even in patients without high expression of CD19 in B-ALL cells.Blinatumomab could be an effective and safe salvage therapy in patients with R/R B-ALL who failed/progressed after anti-CD19-CAR T therapy, even in patients with CNS leukemia or co-infection.
  • ||||||||||  ivabradine / Generic mfg.
    Journal:  Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). (Pubmed Central) -  Jul 10, 2023   
    The higher MACE rate in the non-US/non-Europe vadadustat group may have been partly because of imbalances in the baseline eGFR level in countries where dialysis was not uniformly available resulting in many kidney-related deaths. Our analysis shows that RHR reduction with ivabradine is effective and improves clinical outcomes in HF patients across various risk indicators such as low SBP, high RHR, low LVEF, and high NYHA class to a similar extent and without safety concern.
  • ||||||||||  tarlatamab (AMG 757) / Amgen
    Journal:  Tarlatamab: the promising immunotherapy on its way from the lab to the clinic. (Pubmed Central) -  Jul 10, 2023   
    Our analysis shows that RHR reduction with ivabradine is effective and improves clinical outcomes in HF patients across various risk indicators such as low SBP, high RHR, low LVEF, and high NYHA class to a similar extent and without safety concern. No abstract available
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Development of PROTAC degrader probe of CDK4/6 based on DCAF16. (Pubmed Central) -  Jul 10, 2023   
    Moreover, the toxicity of A4 in normal cells showed 7 times lower than that of Palbociclib, and A4 exhibits therapeutic potential in MDA-MB-231 xenograft models in vivo. These findings indicate that A4, as a novel CDK4/6 degrader based on DCAF16, is worthy of further investigating for the treatment of TNBC.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Blinatumomab Is Safe and Efficacious in Infant Acute Lymphoblastic Leukemia. (Pubmed Central) -  Jul 10, 2023   
    These findings indicate that A4, as a novel CDK4/6 degrader based on DCAF16, is worthy of further investigating for the treatment of TNBC. No toxic effects that led to treatment discontinuation or death were observed with blinatumomab.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Review, Journal:  Intratumoral Immunotherapy: Is It Ready for Prime Time? (Pubmed Central) -  Jul 10, 2023   
    Studies mainly focused on multi-metastatic patients, with some positive trials such as T-VEC in melanoma, but evidence of clinical benefit is still lacking...The clinical benefit might be improved in patients with a low tumor burden. Future clinical trials should focus on adequate timing of treatment delivery during the course of the disease, particularly in the neoadjuvant setting.
  • ||||||||||  Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
    Trial completion date, Mismatch repair:  Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (clinicaltrials.gov) -  Jul 10, 2023   
    P1,  N=52, Active, not recruiting, 
    Future research should focus on confirming these beneficial clinical effects in patients with lower average Lp(a) levels, as well as clearly demonstrating the association between lowering Lp(a) and reducing adverse cardiovascular outcomes. Trial completion date: Jun 2023 --> Jun 2024
  • ||||||||||  Hulio (adalimumab-fkjp) / Fujifilm Kyowa Kirin Biologics, Biocon, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
    Enrollment open:  Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE (clinicaltrials.gov) -  Jul 10, 2023   
    P=N/A,  N=50, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Observational data, Retrospective data, Journal, Adherence:  Investigating the impact of a national educational program on patient adherence to osteoporosis medications. (Pubmed Central) -  Jul 9, 2023   
    However, some patients had a period of treatment discontinuation, placing them at increased risk of fracture. A focused program emphasizing the importance of long-term adherence with denosumab (including switching to bisphosphonates if treatment is discontinued) may be warranted to further improve the quality use of osteoporosis treatment in Australia.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Review, Journal:  Targeting Ras with protein engineering. (Pubmed Central) -  Jul 7, 2023   
    These challenges were recently overcome by the development of the first covalent small-molecule anti-Ras drug, sotorasib, highlighting the efficacy of Ras inhibition as a therapeutic strategy...In parallel, significant advancements have been made in intracellular protein delivery, enabling the delivery of the engineered anti-Ras agents into the cellular cytoplasm. These advances offer a promising path for targeting Ras proteins and other challenging drug targets, opening up new opportunities for drug discovery and development.
  • ||||||||||  D-1553 / InventisBio
    Preclinical, Journal:  D-1553: A novel KRAS inhibitor with potent and selective cellular and in vivo antitumor activity. (Pubmed Central) -  Jul 7, 2023   
    The combination of D-1553 with chemotherapy, MEK inhibitor, or SHP2 inhibitor showed stronger potency on tumor growth inhibition or regression compared to D-1553 alone. These findings support the clinical evaluation of D-1553 as an efficacious drug candidate, both as a single agent or in combination, for patients with solid tumors harboring KRAS mutation.
  • ||||||||||  Long-term insulin independence following allogenic islet transplant and childbirth (Indigo H) -  Jul 7, 2023 - Abstract #IPITAIXACTRMS2023IPITA_IXA_CTRMS_415;    
    5y post-IT and 7y PP with only oral DM medication support. While pregnancy in T1D and immunosuppression remains high risk, this suggests that successful childbirth post-IT can be safely achieved without significantly compromising graft function.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Anti-TNF? as an adjunctive therapy in pancreas transplantation (Indigo H) -  Jul 7, 2023 - Abstract #IPITAIXACTRMS2023IPITA_IXA_CTRMS_97;    
    Combining anti-TNF? and anti-IL1?, as suggested in the field of islet transplantation, will be evaluated in our institution.
  • ||||||||||  AMG 193 / Amgen
    Trial completion date, Trial primary completion date:  A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (clinicaltrials.gov) -  Jul 7, 2023   
    P1/2,  N=386, Recruiting, 
    Trial primary completion date: Feb 2023 --> Aug 2023 Trial completion date: Apr 2028 --> Feb 2027 | Trial primary completion date: Aug 2025 --> Mar 2025